Dobutamine
Β1 sympathomimetic for inotropic support
Dobutamine is a synthetic β1 selective sympathomimetic that has been clinically available since 1978 and is one of the established positive inotropic agents in intensive care medicine. In Germany it is available as an infusion concentrate (Dobutrex and generics) for continuous intravenous administration. The compound is a cornerstone of haemodynamic stabilisation, especially in acute decompensated heart failure with low cardiac output and in cardiogenic shock without severe vasoplegia.
A specific diagnostic application is stress echocardiography with dobutamine to evaluate exertional coronary insufficiency in patients who cannot perform physical exercise. Pharmacological stimulation of the heart simulates the exertional response and reveals ischaemic wall motion abnormalities under echocardiographic imaging.
Mechanism of Action
Dobutamine is a racemic mixture of two enantiomers with different receptor affinities. The plus enantiomer preferentially stimulates myocardial β1 adrenoceptors, while the minus enantiomer additionally has α1 agonist properties. Overall the β1 action predominates with a pronounced positive inotropic effect, followed by a moderate positive chronotropic and mild vasodilatory effect via β2 activation in the vasculature.
Activation of myocardial β1 receptors raises intracellular cAMP, activates protein kinase A and phosphorylates calcium channels and contractile proteins. The result is enhanced contractile force (positive inotropy), accelerated relaxation (positive lusitropy) and an increased cardiac output. Systemic vascular resistance tends to fall, whereas pulmonary vascular resistance is unchanged or slightly reduced.
The half life is only about 2 to 3 minutes, allowing rapid titration. After stopping the infusion the effect subsides within minutes. Breakdown is by catechol O methyltransferase in the liver and other tissues, and metabolites are excreted renally.
Indications
- Acute decompensated heart failure with low cardiac output (cardiac index below 2.2 l/min/m²) and pulmonary congestion
- Cardiogenic shock without severe vasoplegia, usually in combination with noradrenaline
- Perioperative inotropic support after cardiac surgery
- Septic cardiomyopathy as an add on to noradrenaline when myocardial dysfunction is the dominant feature
- Right heart failure with low cardiac output
- Stress echocardiography as a pharmacological exercise alternative in the work up of coronary artery disease
- Acute right heart strain in pulmonary embolism combined with reperfusion therapy
Dosage and Administration
Dobutamine is given exclusively as a continuous intravenous infusion through a central venous catheter. The starting dose is 2.5 µg per kg per minute, with titration in increments of 2.5 µg per kg per minute every 10 to 15 minutes until the desired haemodynamic effect is achieved. The usual dose range is between 2.5 and 20 µg per kg per minute. Higher doses are possible but disproportionately increase the risk of arrhythmia.
Stress echocardiography: standardised protocol starting at 5 µg per kg per minute for 3 minutes, with stepwise escalation to 10, 20, 30 and 40 µg per kg per minute. Atropine can be added to reach the target heart rate. The protocol requires continuous monitoring with ECG, blood pressure and echocardiography.
Renal impairment: no formal adjustment; monitor electrolytes closely. Hepatic impairment: no adjustment required, half life is unchanged. Children: 2 to 20 µg per kg per minute with individual titration in paediatric intensive care. Dilution: in 5 percent glucose or isotonic saline; do not mix with alkaline solutions (bicarbonate, furosemide) because of inactivation.
Side Effects
Very common and common: tachycardia, supraventricular and ventricular arrhythmias (atrial fibrillation, ventricular extrasystoles, ventricular tachycardia), hypertension or hypotension, palpitations, chest pain, headache, tremor, anxiety.
Uncommon: nausea, rash, hypokalaemia, phlebitis at the infusion site, fever, eosinophilia.
Rare and serious: myocardial ischaemia up to infarction in pre existing coronary artery disease, ventricular fibrillation, stress cardiomyopathy (Tako Tsubo) as a paradoxical effect during stress echocardiography, anaphylactic reaction to the sulphur dioxide stabiliser, eosinophilic myocarditis with prolonged therapy.
Tolerance: after 24 to 72 hours of infusion, receptor downregulation develops and tolerance sets in. The dose must be increased to produce the same effect, or therapy is weaned after stabilisation. In chronic heart failure this tolerance is a limiting factor for long term use.
Interactions
- β blockers: attenuate the dobutamine effect; when dobutamine is essential reduce or pause the beta blocker
- α blockers: possible enhanced vasodilation and hypotension
- Other catecholamines (adrenaline, noradrenaline, dopamine): additive effects; often deliberately combined under haemodynamic monitoring
- Inhaled anaesthetics (halothane, enflurane): increased risk of arrhythmia; particular caution during anaesthesia
- Antihypertensives: unpredictable blood pressure responses; monitor closely
- Bicarbonate, alkaline solutions: chemical inactivation; do not administer through the same line
Special Notes
Requirements: use only in an intensive care unit or emergency department with continuous ECG, invasive blood pressure monitoring and defibrillation capability. Volume status must be optimised before starting therapy; in hypovolaemia, inotrope therapy alone is ineffective and potentially harmful.
Contraindications: hypertrophic obstructive cardiomyopathy (worsening of LVOT obstruction), phaeochromocytoma, severe tachyarrhythmia, acute myocardial infarction with a high ischaemic burden, severe anaemia, hypovolaemia without prior volume resuscitation. In hypokalaemia or hypomagnesaemia, correct electrolytes first.
Weaning from dobutamine: therapy should be reduced gradually over hours to days to avoid rebound. Abrupt discontinuation can cause renewed decompensation. When the acute phase has ended, switch to oral heart failure therapy with an ACE inhibitor or ARB, beta blocker, mineralocorticoid receptor antagonist, SGLT 2 inhibitor and diuretic.
Pregnancy: data are limited; use only on vital indication. Breastfeeding: data are lacking; breastfeeding during infusion is not recommended.
Monitoring: continuous ECG, invasive or oscillometric blood pressure, oxygen saturation, urine output, lactate, and where appropriate pulse contour analysis or a pulmonary artery catheter for titration. Check electrolytes at least twice daily.
You might also be interested in
- Vasopressin, vasopressor in intensive care
- Amiodarone, antiarrhythmic for ventricular arrhythmias
- Eplerenone, aldosterone antagonist in heart failure
- Metoprolol succinate, β1 blocker in chronic heart failure therapy
- Enalapril, ACE inhibitor as basic therapy
Frequently Asked Questions
Why is dobutamine only given in the intensive care unit?
The compound has a powerful effect on the cardiovascular system, with relevant risks of arrhythmia, blood pressure swings and ischaemia. Only with continuous ECG, invasive pressure monitoring and immediate defibrillation readiness can dobutamine be used safely. Outpatient use is not technically or legally provided for.
What is dobutamine stress echocardiography?
When patients cannot perform physical exercise (osteoarthritis, severe obesity, neurological disease), the exercise response of the heart is simulated by stepwise increasing doses of dobutamine. The physician uses echocardiography to look for new wall motion abnormalities that indicate ischaemic perfusion disturbance. The technique is an alternative to conventional exercise testing.
What happens with tolerance?
After 24 to 72 hours of continuous infusion, β1 receptors are downregulated and the same dobutamine level has less effect. This is one of the reasons why dobutamine is useful only in the acute phase, and therapy must be switched to oral heart failure medication as soon as haemodynamic stability allows.
Can dobutamine overload the heart?
Yes, with excessive dose or incorrect indication. Enhanced contractile force raises myocardial oxygen consumption, which can trigger ischaemia in pre existing coronary artery disease. For this reason the indication must be set carefully, the dose kept at the lowest effective level and monitoring must be continuous.
Sources
- EMA, European Medicines Agency
- AWMF, guidelines on acute heart failure and cardiogenic shock
- Gelbe Liste, dobutamine drug profile
- BfArM, Federal Institute for Drugs and Medical Devices
Legal Notice and Disclaimer
The information provided on this page is intended solely for general informational purposes and does not constitute medical advice, diagnosis or treatment recommendations. It does not replace consultation with a licensed physician or pharmacist. Medicines should only be taken following a medical prescription or through pharmacy dispensing. All statements are based on the prescribing information and recognised scientific sources published at the time of preparation; the manufacturer’s current prescribing information is always authoritative. Sanoliste accepts no liability for the completeness, timeliness or accuracy of the information presented. In a medical emergency call the emergency number 112.